close

Agreements

Date: 2017-05-15

Type of information: Nomination

Compound:

Company: CytomX Therapeutics (USA - CA)

Therapeutic area: Cancer - Oncology

Type agreement: nomination

Action mechanism:

Disease:

Details:

  • • On May 15, 2017, CytomX Therapeutics announced that Bob Goeltz, chief financial officer, has decided to leave the company to pursue new opportunities. In conjunction with Mr. Goeltz’s departure, CytomX is appointing Debanjan Ray as chief financial officer and head of corporate development, effective immediately. Mr. Ray has been with CytomX since 2011, and most recently served as senior vice president, corporate development and strategy. Prior to joining CytomX in 2011, Mr. Ray was vice president of business development at Itero Biopharmaceuticals. Earlier in his career, Mr. Ray was an associate director of business development at Portola Pharmaceuticals and held positions in the life sciences venture practice at J.P. Morgan Partners and McKinsey & Company. Mr. Ray holds a dual B.S. in chemical engineering and biology from the Massachusetts Institute of Technology and an M.B.A. from The Wharton School, University of Pennsylvania.
  • CytomX is also promoting Danielle Olander to senior vice president, talent and administrative operations.
  • Ms. Olander has led human resources management and operations for more than 20 years and has been a member of the CytomX team since 2014. Prior to CytomX, she served as the senior director of human resources management at Portola Pharmaceuticals. Prior to joining Portola, Ms. Olander held positions at SuperGen (now Astex Pharmaceuticals), Sugen (acquired by Pfizer) and Kinetic Search. She received her B.S. in human resource management from Colorado Technical University. She is chairperson of the Biotechnology HR Network and an active member of the Society for Human Resources Management and World at Work, The Total Rewards Association.

Financial terms:

Latest news:

Is general: Yes